BIO KEY INTERNATIONAL INC

For the period ended Mar 31, 2026. Filed Jun 22, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Jun 22, 2026

BKYI$2.39+0.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,	December 31,
	2026	2025
(Unaudited)
ASSETS
Cash and cash equivalents	$2,247,984	$2,694,663
Accounts receivable, net	1,573,454	1,220,822
Inventory	338,397	370,879
Prepaid expenses and other	326,043	251,323
Total current assets	4,485,878	4,537,687
Equipment and leasehold improvements, net	53,035	67,751
Capitalized contract costs, net	294,415	311,591
Deposits and other assets	7,976	7,976
Operating lease right-of-use assets	41,383	47,953
Investments	2,500,000	2,500,000
Intangible assets, net	774,318	830,357
Total non-current assets	3,671,127	3,765,628
TOTAL ASSETS	$8,157,005	$8,303,315
LIABILITIES
Accounts payable	$514,197	$507,357
Accrued liabilities	1,127,099	1,333,930
Note payable	651,935	604,102
Government loan – BBVA Bank, current portion	12,351	50,530
Deferred revenue, current	855,276	572,513
Operating lease liabilities, current portion	29,501	27,728
Total current liabilities	3,190,359	3,096,160
Deferred revenue, long term	45,225	62,584
Deferred tax liability	16,500	16,500
Operating lease liabilities, net of current portion	12,908	21,266
Total non-current liabilities	74,633	100,350
TOTAL LIABILITIES	3,264,992	3,196,510
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Common stock — authorized, 170,000,000 shares; issued and outstanding; 1,085,360 of $.0001 par value at March 31, 2026 and December 31, 2025, respectively	109	109
Additional paid-in capital	141,538,485	141,497,741
Accumulated other comprehensive income	24,304	74,803
Accumulated deficit	(136,670,885)	(136,465,848)
TOTAL STOCKHOLDERS’ EQUITY	4,892,013	5,106,805
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$8,157,005	$8,303,315

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Three Months Ended
	March 31,
	2026	2025
Revenues
Services	$248,384	$272,598
License fees	1,365,893	1,098,758
Hardware	531,256	235,803
Total revenues	2,145,533	1,607,159
Costs and other expenses
Cost of services	78,498	98,144
Cost of license fees	73,234	72,885
Cost of hardware	323,538	108,469
Cost of hardware - reserve	(98,970)	-
Total costs and other expenses	376,300	279,498
Gross profit	1,769,233	1,327,661
Operating expenses
Selling, general and administrative	1,310,066	1,372,524
Research, development and engineering	616,880	595,775
Total operating expenses	1,926,946	1,968,299
Operating loss	(157,713)	(640,638)
Other income (expense)
Interest income	675	3
Loan fee amortization	(20,833)	(60,000)
Interest expense	(27,166)	(35,910)
Total other income (expense), net	(47,324)	(95,907)
Loss before provision for income taxes (tax benefits)	(205,037)	(736,545)
Provision for income taxes (tax benefits)	-	-
Net loss	$(205,037)	$(736,545)
Comprehensive loss:
Net loss	$(205,037)	$(736,545)
Other comprehensive income (loss) – foreign currency translation adjustment	(50,499)	6,803
Comprehensive loss	$(255,536)	$(729,742)
Basic and diluted loss per common share	$(0.20)	$(1.57)
Weighted average common shares outstanding:
Basic and diluted	1,035,147	470,242

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.